BioNTech SE is 15.7x more valuable than Monte Rosa Therapeutics, Inc. by market capitalization ($21.79 B vs $1.39 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | GLUE | BNTX |
|---|---|---|
| Market cap | $1.39 B | $21.79 B |
| US-listed rank | #2397 | #587 |
| Net income (latest FY) | -$38.60M | - |
| SEC filings | 352 | 548 |
BioNTech SE is 15.7x more valuable than Monte Rosa Therapeutics, Inc. by market capitalization ($21.79 B vs $1.39 B).
Full pages: Monte Rosa Therapeutics, Inc. and BioNTech SE, or browse the full rankings.